Status:
UNKNOWN
Effect of Growth Hormone in Metabolic Syndrome
Lead Sponsor:
Chinese University of Hong Kong
Conditions:
Metabolic Syndrome
Eligibility:
MALE
35-50 years
Phase:
PHASE4
Brief Summary
Investigating the effect of low dose growth hormone therapy on body fat composition, insulin sensitivity and metabolic profiles in middle-aged men with metabolic syndrome and low insulin-like growth f...
Detailed Description
Metabolic syndrome, a constellation of glucose intolerance, hypertension, dyslipidemia, obesity, pro-inflammatory and prothrombotic state culminating to development of premature cardiovascular disease...
Eligibility Criteria
Inclusion
- Age 35 to 50 Chinese men
- Metabolic syndrome as defined according to 1998 World Health Organisation with modification using Asian definition for obesity (body mass index 25kg/m2, waist circumference 80cm in women and 90 cm in men)
- Low IGF-1 level or IGF-1 level in low normal range (\<200 ug/L)
Exclusion
- Any malignancy within the past 5 years
- A diagnosis of acromegaly
- Uncontrolled hypertension (systolic blood pressure \>180mmHg or diastolic blood pressure\>105mmHg)
- A history of carpel tunnel syndrome
- Poor glycemic control (HbA1c\>8%)
- Diabetic microangiopathy
- Previous cardiovascular event
- Anaemia as defined as haemoglobin \<11g/dL
- Active thyroid diseases
- Any medical illness that will render the subject vulnerable to fluid retention state, e.g. renal impairment, heart failure or as judged by the investigators as ineligible to participate the study.
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
End Date :
July 1 2007
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT00307411
Start Date
August 1 2006
End Date
July 1 2007
Last Update
April 4 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Prince of Wales Hospital, The Chinese University of Hong Kong
Hong Kong SAR, China